Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > This gives me less and less and less confidence
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(310)
•••
Comment by AngelaLon Feb 07, 2021 3:40pm
147 Views
Post# 32496560

RE:RE:RE:RE:RE:This gives me less and less and less confidence

RE:RE:RE:RE:RE:This gives me less and less and less confidenceSalzman has published in world-class publications if you took the time to read the list. Journals like PNAS, Circulation Research, Journal of Inmunology, Gastroebterokogy, etc. From the bio on the website of his company it's clear he left academia in 1999 so that it is not at all surprising that he didn't publish mich after that. He was the first to develop PARP inhibitors for humans, a drug class which is now a mainstay in treatment of breast and ovarian cancer. Look at his partnering deal with Genentech, the world's top cancer company, which licensed his invention (see link below). You'd be way off base not to regard this guy as world class. By the way, have you done 1% of what he's accomplished?

https://www.pharmaceuticalonline.com/doc/genentech-inc-inotek-pharmaceuticals-corporat-0001



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities